Diagnostic Biomarkers of Neurodegeneration in Multiple Sclerosis
Production of intrathecal immunoglobulin G and neurofilament light chain levels may have a diagnostic value in multiple sclerosis.
All articles by Neurology Advisor Contributing Writer
Qualitative Analysis of Visual Symptoms in Childhood Migraine
Investigators examined the characteristics of visual symptoms during migraine attacks in children and adolescents.
Infection Risk With Second-Generation Disease-Modifying Treatments in MS
Investigators examined the association between infection-related medical encounters and disease-modifying treatments for multiple sclerosis.
Intravenous Aminophylline Safe and Effective for Postdural Puncture Headache
Investigators examine the safety and efficacy of intravenous aminophylline for postdural puncture headaches.
Blood-Brain Barrier Permeability Predicts Treatment Response in MS
Investigators sought to determine sub-optimal treatment response in RRMS by measuring the blood-brain barrier permeability by MRI.
Increased Risk of Developing Hypertension in Women With Migraine
Investigators conducted a prospective cohort study to examine the risk of incident hypertension in women with migraine.
New Zolmitriptan Intracutaneous System Safe and Effective for Migraine
Researchers conducted a randomized, double-blond, placebo-controlled, dose-ranging trial to assess the use of a new zolmitriptan intracutaneous delivery system in adults with migraine headache.
DBS Improves Inpatient Outcomes for Comorbid Parkinson Disease and Depression
Researchers sought to assess outcomes in hospitalized patients with comorbid Parkinson disease and major depressive disorder following administration of deep brain stimulation.
Adjunctive Eslicarbazepine Safe and Well Tolerated for Pediatric Seizures
Researchers conducted post-hoc analysis of data derived from 2 randomized, placebo-controlled trials to determine the safety and tolerability of eslicarbazepine in pediatric patients with partial-onset seizures not responsive to treatment with ≤2 antiepileptic drugs.
Erenumab Shown to Reduce Headache Days for Patients with Episodic Migraine
Researchers assessed the ability of erenumab to decrease the mean number of acute headache days in patients with episodic migraine.
- Loading...
Loading...
Next post in AAN 2018 Coverage
Loading... 
Loading...